ADX-2191

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company dedicated to developing novel therapies for immune-mediated diseases through its proprietary Reactive Aldehyde Species (RASP) modulator platform. Its lead asset, reproxalap, is under regulatory review for dry eye disease following a Complete Response Letter, while its pipeline includes ADX-2191 for rare retinal diseases and an oral systemic candidate, ADX-629. The company's strategy hinges on validating its RASP platform through regulatory approval in ophthalmology, then expanding into broader systemic inflammatory and metabolic disorders with significant unmet need.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company dedicated to developing novel therapies for immune-mediated diseases through its proprietary Reactive Aldehyde Species (RASP) modulator platform. Its lead asset, reproxalap, is under regulatory review for dry eye disease following a Complete Response Letter, while its pipeline includes ADX-2191 for rare retinal diseases and an oral systemic candidate, ADX-629. The company's strategy hinges on validating its RASP platform through regulatory approval in ophthalmology, then expanding into broader systemic inflammatory and metabolic disorders with significant unmet need.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company dedicated to developing novel therapies for immune-mediated diseases through its proprietary Reactive Aldehyde Species (RASP) modulator platform. Its lead asset, reproxalap, is under regulatory review for dry eye disease following a Complete Response Letter, while its pipeline includes ADX-2191 for rare retinal diseases and an oral systemic candidate, ADX-629. The company's strategy hinges on validating its RASP platform through regulatory approval in ophthalmology, then expanding into broader systemic inflammatory and metabolic disorders with significant unmet need.

Therapeutic Areas